Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Rank in Stocks #33381
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Share Price
$5.49
Market Cap
$8.02M
Change (1 day)
-0.54%
Change (1 year)
7.86%
Country
US
Trade CNS Pharmaceuticals, Inc. (CNSP)

Category

Dividend yield history for CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (stock symbol: CNSP) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for CNS Pharmaceuticals, Inc. (CNSP) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors